top of page

Tokyo District Court, 2016 (Wa) 25436 [Method for Constructing Amino Acid-Producing Bacteria] <Damages>

1 day ago
4 min read

Updated: 2 hours ago

Article information

Article type: Case note

Classification: Patents

Issues: Damages

First published on this website: 2026-11-20

Case numbers: 2016 (Wa) 25436

Display and classification checked: 2026-11-21


Article date: 2023-08-07


Tokyo District Court, 2016 (Wa) 25436 [Method for Constructing Amino Acid-Producing Bacteria] <Damages>

<Rebuttal of the Article 102(2) presumption: 50% rebutted>

Competing products (allocation according to market share)

<Grounds for rebutting the presumption>

Sales of competing products (reduction according to market share)

⇒ There is no evidence establishing the volume imported from Indonesia by businesses other than the plaintiff. Nevertheless, at least approximately 50% of the demand for the MSG sold by the defendants may have shifted to monosodium glutamate imported and sold by parties other than the plaintiff.

<Contribution rate> Production of glutamic acid by fermentation includes fermentation and purification stages, with multiple reactions within the strain during fermentation. Even if the invention concerns only a particular stage or reaction, this does not establish that the patented inventions made a low contribution to production of the MSG at issue.

(Extract from the court's reasoning)

 Grounds for rebutting the presumption

(A) Sales of competing products (reduction according to market share)

  a. The evidence (Otsu 101, 117) and the entire purport of oral argument establish that imports of monosodium glutamate into Japan from each country during the periods in which the defendants' respective processes were used were as stated in columns ①–⑩ of Appendix 16, "Imports of Monosodium Glutamate during the Periods of Use of the Defendants' Respective Processes." Of these, all imports from ① Thailand and ② Brazil were imported by the plaintiff and sold in Japan. Imports from ③ Indonesia included imports by the plaintiff as well as the quantities sold by the defendants (③A). For calculation of the 2017 figures, the quantities in Attachment 7, rather than Attachment 6, to Exhibit Otsu 101 were used as data comparable to the 2011–28 materials (Otsu 117).

  b. The MSG at issue is monosodium glutamate. All monosodium glutamate described in a above that was imported during the periods of use of the defendants' respective processes is found to constitute products competing in the Japanese market as equivalents of the MSG sold by the defendants.

 The existence of these competing products, in addition to those sold by the defendants and imported and sold by the plaintiff, should be considered a circumstance warranting rebuttal of the presumption under Patent Act Article 102(2) for part of the total marginal profits of the defendants described in E above.

  c. The rebuttal rate based on these circumstances is considered below.

 Regarding the quantity (③B) of imports from ③ Indonesia other than the defendants' sales (③A), the defendant argues that half is presumed attributable to businesses other than the plaintiff. However, there is no evidence establishing the volume imported from Indonesia by such other businesses.

 Taking account of the plaintiff's assertion that it accounted for almost all of quantity ③B, and assuming that this quantity was imported by the plaintiff, the plaintiff's imports and sales (⑪) are calculated. The ratio of those imports and sales (⑪) to the quantity obtained by deducting the defendants' sales (③A) from total imports (⑩), is then calculated. As shown in that appendix, the annual ratios during the periods of use of the defendants' processes range from ●(omitted)●% to ●(omitted)●%, and the annual average is calculated as 44.7%.

 Regarding the Ministry of Finance trade statistics submitted by the defendant (Otsu 117, Materials 3–10), the plaintiff also argues that quantities not included in those materials were imported as glutamic acid and processed domestically into monosodium glutamate, and that almost all such imports were by the plaintiff. However, it has submitted no specific supporting materials, and the evidence (Otsu 101, Attachment 7) suggests that imports of such glutamic acid were small compared with imports of monosodium glutamate.

 Thus, even taking the plaintiff's arguments into account, it is appropriate to find that, had the defendants' quantities not been sold during the periods of use of their respective processes, at least approximately 50% of the demand for the MSG they sold might have shifted to monosodium glutamate imported and sold by parties other than the plaintiff. A 50% rebuttal of the presumption on this basis is appropriate.

 (B) Degree of contribution of the patents at issue to damages

 The defendant argues that the inventions covered by these patents contribute only to a very small part of the complex and diverse processes for producing glutamic acid, and that their respective contributions to producing the MSG at issue are low. It therefore argues that calculation of damages under Patent Act Article 102(2) should take account of each patent's contribution rate, or alternatively that rebuttal should be allowed according to those contribution rates.

 However, Invention 1-1 (Corrected Invention 1-1), Invention 1-2 (Corrected Invention 1-2), Invention 1-4 (Corrected Invention 1-3), and Invention 2-5 (Corrected Invention 2-5), all found to have been worked during the periods of use of the defendants' respective processes, are inventions of methods of producing glutamic acid (an amino acid) using strains with particular characteristics. Where working of these patented inventions is established through sales or other acts involving MSG produced with those strains, each patented invention must be regarded as worked in relation to the entirety of the MSG sold.

 Production of glutamic acid by fermentation includes fermentation and purification stages, with multiple reactions within the strain during fermentation. Even if these patented inventions concern only particular stages or reactions, that does not establish that their contributions to production of the MSG were low. Nor does any other evidence establish circumstances warranting rebuttal of the Article 102(2) presumption for the claims based on these patents on grounds of their contribution rates. The defendant's argument cannot therefore be accepted.

Update history

This history records changes actually made to publication, display, and classification on this website.

20 November 2026: First published on this website.

21 November 2026: Article type, classification, issues, related articles, consultation links, and SEO were maintained. The original text was not changed.

Comments


Featured Posts

Recent Posts

Archive
Search by Tags
Follow Us
  • Facebook Basic Square
  • Twitter Basic Square
  • Google+ Basic Square
bottom of page